Condensed Consolidated Statements Of Income And Comprehensive Income (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Revenue
Pharmaceutical net sales	$ 261,412	$ 177,045	$ 471,180	$ 303,817
Contract manufacturing net sales	17,418	7,528	34,754	15,885
Total net sales	278,830	184,573	505,934	319,702
Cost of sales	23,152	17,221	44,562	33,410
Gross profit	255,678	167,352	461,372	286,292
Operating expenses:
Selling and marketing	56,792	37,900	103,859	73,362
General and administrative	26,848	13,126	49,475	25,675
Research and development	22,008	12,240	41,937	23,033
Depreciation and amortization	1,065	1,014	2,092	2,084
Change in fair value of contingent consideration	1,201	0	2,382	0
Impairment of goodwill and intangibles	0	0	0	719
Total operating expenses	107,914	64,280	199,745	124,873
Income from operations	147,764	103,072	261,627	161,419
Interest and other income (expense), net	(226)	20	(1,018)	(322)
Foreign currency transaction gain (loss)	60	0	(94)	(488)
Income before income taxes	147,598	103,092	260,515	160,609
Income tax expense	51,162	33,969	89,769	52,424
Net income	96,436	69,123	170,746	108,185
Change in unrealized gains or losses on available-for-sale securities, net of related tax effects	31	(29)	37	(34)
Change in foreign currency translation adjustments	1,479	(1,451)	242	(2,640)
Comprehensive income	$ 97,946	$ 67,643	$ 171,025	$ 105,511
Net income per share:
Basic	$ 1.62	$ 1.17	$ 2.87	$ 1.86
Diluted	$ 1.54	$ 1.12	$ 2.75	$ 1.79
Shares used in computing net income per share:
Basic	59,686	58,938	59,415	58,075
Diluted	62,451	61,498	62,172	60,581
Dividends declared per share of common stock	$ 0.3	$ 0.25	$ 0.6	$ 0.50